Deciphera Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on oncology. It was founded in 2003 and built around a proprietary drug-discovery platform designed to target kinase signaling pathways and develop medicines for cancers with significant unmet medical need. For French-speaking investors, Deciphera should be viewed as a specialty biotech rather than a broad-based pharmaceutical conglomerate: its value proposition has centered on precision oncology, clinical differentiation, and regulatory execution. The company is associated with the U.S. market, having traded on NASDAQ, and it is headquartered in Waltham, Massachusetts, United States. ([deciphera.com](https://www.deciphera.com/about?utm_source=openai)) Commercially, Deciphera’s portfolio was anchored by QINLOCK (ripretinib), an oral therapy for advanced gastrointestinal stromal tumor (GIST), and later expanded with ROMVIMZA (vimseltinib), which received full FDA approval in February 2025 for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) where surgery could worsen functional limitation or cause severe morbidity. That approval was an important validation event for the company’s internal R&D engine and demonstrated its ability to advance a molecule from discovery through late-stage development and into the market. The company also continued to advance other programs, including tirabrutinib, for which the FDA accepted an NDA in 2026 in a hematology/oncology setting. ([deciphera.com](https://www.deciphera.com/news/us-fda-grants-full-approval-decipheras-romvimzatm-vimseltinib-treatment-symptomatic?utm_source=openai)) From a competitive standpoint, Deciphera operates in a crowded oncology landscape where differentiation depends on clinical efficacy, safety, convenience, and the ability to secure regulatory and reimbursement support. Its strategy has been to focus on selected rare or underserved indications, which can create attractive commercial opportunities if clinical data are strong. The company’s geographic footprint has primarily been in the United States, with international development and commercialization efforts supported through partnerships and regulatory filings outside the U.S., including Europe. ([fintel.io](https://fintel.io/doc/sec-deciphera-pharmaceuticals-inc-1654151-10k-2024-february-07-19760-2425?utm_source=openai)) A major recent milestone reshaped the equity story: Deciphera was acquired by Ono Pharmaceutical, with completion announced in June 2024. The company stated that Deciphera shares ceased trading on NASDAQ after the transaction closed. For investors, that means current references to Deciphera are best understood in a historical or corporate-structure context rather than as a live standalone listed equity. Deciphera now operates as a wholly owned subsidiary within Ono’s group, which changes how one should interpret insider filings, valuation, and standalone market analysis. ([deciphera.com](https://www.deciphera.com/news/deciphera-pharmaceuticals-be-acquired-ono-pharmaceutical-24-billion?utm_source=openai))